Novavax (NVAX) says phase 1 data for COVID-19 vaccine candidate show it was generally well-tolerated and elicited robust antibody responses

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to Novavax (NVAX) says phase 1 data for COVID-19 vaccine candidate show it was generally well-tolerated and elicited robust antibody responses

Novavax (NVAX) PT Raised to $257 at B.Riley/FBR

August 5, 2020 6:57 AM EDT

B.Riley/FBR analyst Chad L. Mabry raised the price target on Novavax (NASDAQ: NVAX) to $257.00 (from $184.00) while maintaining a Buy rating.

... More

Novavax (NVAX) Reports Positive Phase 1 Data for COVID-19 Vaccine Candidate

August 5, 2020 6:24 AM EDT

Novavax, Inc. (NASDAQ: NVAX) today announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID19 vaccine with and without MatrixM adjuvant in healthy adults 18-59 years of age. NVXCoV2373, the Companys recombinant COVID-19 vaccine candidate adjuvanted with Matrix-M, was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. The data have been submitted for peer-review to a scientific journal and to an online preprint server at medRxiv.org.

NVX-CoV2373 was well-tolerated and had a reassuring safety profile.
Overall,... More

Novavax (NVAX) Erases Post-Market Decline, Now Up 13%

August 4, 2020 5:46 PM EDT

Novavax (NASDAQ: NVAX) Erases Post-Market Decline, Now Up 13%

... More